Recombinant Lectin Formulation for Long-Term Protein Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of recombinant lectins from Sclerotium rolfsii lack stability and conformational integrity, making them challenging to develop into effective cancer treatments due to chemical and physical instability, which affects their solubility and bioactivity.
Innovation Solution
A stable pharmaceutical composition comprising recombinant lectin proteins from Sclerotium rolfsii, formulated with pharmaceutically acceptable excipients such as amino acid Arginine or its salt, surfactants, and sucrose, to maintain stability and bioactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If recombinant lectin proteins are formulated without stabilizers, then the formulation is simpler, but the proteins suffer from chemical and physical instability leading to degradation
Solution Approach 1:
The patent introduces multiple excipients (arginine, surfactants, sucrose) as intermediary substances that mediate between the recombinant lectin proteins and the formulation environment. These excipients act as protective intermediaries that prevent direct interaction between the proteins and destabilizing factors, thereby maintaining protein stability without requiring complex formulation systems
Solution Approach 2:
The patent creates a composite pharmaceutical formulation by combining recombinant lectin proteins with multiple excipients (arginine, surfactants, and sucrose). This composite material approach allows each component to contribute specific stabilizing properties, with arginine preventing deamidation, surfactants preventing aggregation, and sucrose providing structural support, collectively achieving enhanced protein stability
2Ease of operation
If lectin proteins are stored at room temperature, then storage and handling is easier, but the proteins undergo degradation and lose bioactivity
Solution Approach 1:
The patent modifies the chemical environment parameters of the protein formulation by incorporating excipients that alter the local microenvironment around the proteins. Arginine changes the ionic environment to prevent deamidation, surfactants modify the surface properties to prevent aggregation, and sucrose changes the viscosity and molecular mobility, collectively enabling stable storage at room temperature while retaining bioactivity
Solution Approach 2:
The patent applies beforehand cushioning by incorporating stabilizing excipients into the formulation before storage. These excipients pre-establish protective mechanisms that cushion the proteins against thermal degradation, oxidation, and aggregation that would otherwise occur during room temperature storage, thereby preserving bioactivity without requiring refrigeration
3Duration of action of stationary object
If the lectin formulation is designed for long-term stability, then therapeutic efficacy is maintained, but the formulation requires multiple excipients increasing complexity
Solution Approach 1:
The patent merges multiple stabilizing functions into a coordinated excipient system where arginine, surfactants, and sucrose work synergistically. Each excipient addresses specific degradation pathways (deamidation, aggregation, oxidation), and their combined effect provides comprehensive long-term stability. This merging of functions allows the formulation to achieve extended shelf life while maintaining manageable complexity through the use of well-established, compatible excipients
Data Source
AI summary
The present invention relates to stable formulations of recombinant proteins. The invention specifically relates to the formulations of recombinant lectins derived from Sclerotium rolfsii lectin. The formulation comprises recombinant lectin derived from Sclerotium rolfsii lectin and a pharmaceutically acceptable excipient. The invention also relates to the stable liquid and/or lyophilized formulations comprising recombinant lectins derived from Sclerotium rolfsii lectin.